101 related articles for article (PubMed ID: 8201530)
1. Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys.
Shibasaki M; Usui T; Inagaki O; Asano M; Takenaka T
J Pharm Pharmacol; 1994 Jan; 46(1):68-72. PubMed ID: 8201530
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological properties of YM-21095, a potent and highly specific renin inhibitor.
Shibasaki M; Asano M; Fukunaga Y; Usui T; Ichihara M; Murakami Y; Nakano K; Fujikura T
Am J Hypertens; 1991 Dec; 4(12 Pt 1):932-8. PubMed ID: 1815649
[TBL] [Abstract][Full Text] [Related]
3. KRI-1314: an orally effective inhibitor of human renin.
Etoh Y; Miyazaki M; Saitoh H; Toda N
Jpn J Pharmacol; 1993 Sep; 63(1):109-19. PubMed ID: 8271523
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a well-absorbed, efficacious renin inhibitor, A-74273.
Kleinert HD; Stein HH; Boyd S; Fung AK; Baker WR; Verburg KM; Polakowski JS; Kovar P; Barlow J; Cohen J
Hypertension; 1992 Dec; 20(6):768-75. PubMed ID: 1452292
[TBL] [Abstract][Full Text] [Related]
5. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
6. An orally active renin inhibitor: cyclohexylnorstatine-containing dipeptide (KRI-1314).
Miyazaki M; Etoh Y; Iizuka K; Toda N
J Hypertens Suppl; 1989 Apr; 7(2):S25-7. PubMed ID: 2666609
[TBL] [Abstract][Full Text] [Related]
7. A novel nonpeptidic, orally active renin inhibitor.
Morishima H; Koike Y; Nakano M; Atsuumi S; Tanaka S; Funabashi H; Hashimoto J; Sawasaki Y; Mino N; Nakano M
Biochem Biophys Res Commun; 1989 Mar; 159(3):999-1005. PubMed ID: 2495004
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril.
Fossa AA; Weinberg LJ; Barber RL; Rauch AL; Nocerini MR; Murphy WR; Swindell AC
J Cardiovasc Pharmacol; 1992 Jul; 20(1):75-82. PubMed ID: 1383634
[TBL] [Abstract][Full Text] [Related]
9. [In vitro and in vivo inhibition of renin by a thiazolylalanyl cyclostatine derivative].
Muneta S
Nihon Jinzo Gakkai Shi; 1989 Aug; 31(8):865. PubMed ID: 2512401
[TBL] [Abstract][Full Text] [Related]
10. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
11. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
McCaa RE; Gillespie JB
Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of CI-992 following intravenous and oral administration to cynomolgus monkeys.
Cook JA; Burger PJ; Michniewicz BM; Nordblom GD; Hicks GW; Kaplan C; Ryan MJ
Biopharm Drug Dispos; 1998 Apr; 19(3):185-91. PubMed ID: 9570002
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular actions of the primate-selective renin inhibitor, A-62198.
Kleinert HD; Martin D; Chekal M; Young G; Rosenberg S; Plattner JJ; Perun TJ
J Pharmacol Exp Ther; 1988 Sep; 246(3):975-9. PubMed ID: 3047366
[TBL] [Abstract][Full Text] [Related]
14. Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca.
Lacour C; Cazaubon C; Roccon A; Segondy D; Wagnon J; Nisato D
J Hypertens Suppl; 1989 Apr; 7(2):S33-5. PubMed ID: 2666612
[TBL] [Abstract][Full Text] [Related]
15. [Hypotensive action of human renin inhibitor KRI-1314 in the common marmoset].
Saitoh H; Etoh Y; Murakami M; Kubota T; Miyazaki M
Nihon Yakurigaku Zasshi; 1994 Apr; 103(4):161-73. PubMed ID: 8175079
[TBL] [Abstract][Full Text] [Related]
16. Effects of high doses of A-74273, a novel nonpeptidic and orally bioavailable renin inhibitor.
Verburg KM; Polakowski JS; Kovar PJ; Klinghofer V; Barlow JL; Stein HH; Mantei RA; Fung AK; Boyd SA; Baker WR
J Cardiovasc Pharmacol; 1993 Jan; 21(1):149-55. PubMed ID: 7678671
[TBL] [Abstract][Full Text] [Related]
17. Effects of renin inhibition compared to angiotensin converting enzyme inhibition in conscious dogs with pacing-induced heart failure.
Shannon RP; Friedrich S; Mathier M; Knight DR
Cardiovasc Res; 1997 Jun; 34(3):464-72. PubMed ID: 9231029
[TBL] [Abstract][Full Text] [Related]
18. Effect of an orally active renin inhibitor Cl-992 on blood pressure in normotensive and hypertensive monkeys.
Ryan MJ; Hicks GW; Batley BL; Rapundalo ST; Patt WC; Taylor DG; Keiser JA
J Pharmacol Exp Ther; 1994 Jan; 268(1):372-9. PubMed ID: 8301578
[TBL] [Abstract][Full Text] [Related]
19. Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity.
Kleinert HD; Martin D; Chekal MA; Kadam J; Luly JR; Plattner JJ; Perun TJ; Luther RR
Hypertension; 1988 Jun; 11(6 Pt 2):613-9. PubMed ID: 3292414
[TBL] [Abstract][Full Text] [Related]
20. Effects of prolonged and brief infusions of noradrenaline on arterial pressure and on the plasma concentrations of active renin, angiotensin II, aldosterone and potassium.
Casals-Stenzel J; Tree M; Brown JJ; Fraser R; Lever AF; Millar JA; Morton JJ; Robertson JI; Reid JL; Hamilton C
J Hypertens; 1983 Jun; 1(1):27-35. PubMed ID: 6397510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
